NextCure Inc (NXTC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NextCure Inc (NXTC) has a cash flow conversion efficiency ratio of -0.800x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.71 Million) by net assets ($12.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of NextCure Inc for the company's overall valuation and market capitalisation.
NextCure Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how NextCure Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NextCure Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NextCure Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of NextCure Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Milae Bioresources Co. Ltd
KQ:218150
|
-0.006x |
|
Inspira Technologies Oxy BHN Ltd
NASDAQ:IINN
|
0.001x |
|
Bayfirst Financial Corp
NASDAQ:BAFN
|
0.540x |
|
Delta Resources Ltd
V:DLTA
|
-0.144x |
|
Scandinavian Investment Group A/S
CO:SIG
|
0.046x |
|
Nitiraj Engineers Limited
NSE:NITIRAJ
|
-0.097x |
|
Pusan Cast Iron Co., Ltd.
KO:005030
|
0.020x |
|
Assems Inc.
KQ:136410
|
0.026x |
Annual Cash Flow Conversion Efficiency for NextCure Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of NextCure Inc from 2017 to 2025. View NextCure Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $34.94 Million | $-49.61 Million | -1.420x | -127.81% |
| 2024-12-31 | $65.47 Million | $-40.80 Million | -0.623x | -34.62% |
| 2023-12-31 | $114.42 Million | $-52.97 Million | -0.463x | -43.94% |
| 2022-12-31 | $167.53 Million | $-53.89 Million | -0.322x | -31.14% |
| 2021-12-31 | $233.39 Million | $-57.24 Million | -0.245x | -60.26% |
| 2020-12-31 | $293.72 Million | $-44.95 Million | -0.153x | -38.12% |
| 2019-12-31 | $321.48 Million | $-35.62 Million | -0.111x | +34.91% |
| 2018-12-31 | $-46.94 Million | $7.99 Million | -0.170x | -133.21% |
| 2017-12-31 | $-24.41 Million | $-12.51 Million | 0.513x | -- |
About NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leuke… Read more